ruxolitinib cream atopic
Selected indexed studies
- Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. (J Am Acad Dermatol, 2021) [PMID:33957195]
- Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis. (Am J Clin Dermatol, 2023) [PMID:36538235]
- Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. (J Allergy Clin Immunol, 2020) [PMID:31629805]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- JAK inhibitors in the treatment of atopic dermatitis. (2021) pubmed
- Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis. (2023) pubmed
- Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. (2021) pubmed
- Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. (2025) pubmed
- Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. (2020) pubmed
- Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis. (2023) pubmed
- Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. (2024) pubmed
- Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. (2025) pubmed
- Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta-analysis. (2026) pubmed
- Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis. (2025) pubmed